{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:33:05Z","timestamp":1775136785357,"version":"3.50.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2013,9,9]],"date-time":"2013-09-09T00:00:00Z","timestamp":1378684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0073543","type":"journal-article","created":{"date-parts":[[2013,9,9]],"date-time":"2013-09-09T18:41:01Z","timestamp":1378752061000},"page":"e73543","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Metabolic Glucose Status and Pituitary Pathology Portend Therapeutic Outcomes in Acromegaly"],"prefix":"10.1371","volume":"8","author":[{"given":"Sonia","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rany","family":"Al-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula B.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Serri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"L. Asa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shereen","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,9,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00005792-199409000-00001","article-title":"Acromegaly. Clinical and biochemical features in 500 patients","volume":"73","author":"S Ezzat","year":"1994","journal-title":"Medicine"},{"key":"ref2","first-page":"29","article-title":"Canadian consensus guidelines for the diagnosis and management of acromegaly","volume":"29","author":"S Ezzat","year":"2006","journal-title":"Clinical and investigative medicine Medecine clinique et experimentale"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0889-8529(05)70278-4","article-title":"Acromegaly","volume":"26","author":"S Ezzat","year":"1997","journal-title":"Endocrinology and metabolism clinics of North America"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000012275","article-title":"Psychological features of acromegaly","volume":"67","author":"K Furman","year":"1998","journal-title":"Psychotherapy and psychosomatics"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: Acromegaly","volume":"355","author":"S Melmed","year":"2006","journal-title":"The New England journal of medicine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11154-007-9063-z","article-title":"Acromegaly: re-thinking the cancer risk","volume":"9","author":"S Loeper","year":"2008","journal-title":"Reviews in endocrine & metabolic disorders"},{"key":"ref7","first-page":"3132","article-title":"Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly","volume":"85","author":"A Colao","year":"2000","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1530\/eje.1.01955","article-title":"Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly","volume":"153","author":"SW van Thiel","year":"2005","journal-title":"European journal of endocrinology\/European Federation of Endocrine Societies"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/jc.2003-030915","article-title":"Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly","volume":"89","author":"O Serri","year":"2004","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref10","first-page":"1012","article-title":"Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy","volume":"74","author":"N Moller","year":"1992","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"AL Barkan","year":"2005","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2265.2008.03469.x","article-title":"Long-term experience of pegvisomant therapy as a treatment for acromegaly","volume":"71","author":"CE Higham","year":"2009","journal-title":"Clinical endocrinology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ghir.2011.03.004","article-title":"Combination treatment with somatostatin analogues and pegvisomant in acromegaly","volume":"21","author":"SJ Neggers","year":"2011","journal-title":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0889-8529(18)30212-3","article-title":"Living with acromegaly","volume":"21","author":"S Ezzat","year":"1992","journal-title":"Endocrinology and metabolism clinics of North America"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"S Bhayana","year":"2005","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/EJE-08-0243","article-title":"The influence of age on the GH-IGF1 axis in patients with acromegaly","volume":"159","author":"K Tanimoto","year":"2008","journal-title":"European journal of endocrinology\/European Federation of Endocrine Societies"},{"key":"ref17","unstructured":"Asa S (1998) Atlas of Tumor Pathology; Pathology AFIo, editor. Washington: American Registry of Pathology."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S4.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20132011 update","volume":"17","author":"L Katznelson","year":"2011","journal-title":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4158\/EP.10.3.213","article-title":"AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly","volume":"10","author":"DM Cook","year":"2004","journal-title":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1210\/jc.2004-2466","article-title":"A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly","volume":"90","author":"S Melmed","year":"2005","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1530\/eje.1.02036","article-title":"Consensus statement: medical management of acromegaly","volume":"153","author":"S Melmed","year":"2005","journal-title":"European journal of endocrinology\/European Federation of Endocrine Societies"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"S Melmed","year":"2009","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrc926","article-title":"The pathogenesis of pituitary tumours","volume":"2","author":"SL Asa","year":"2002","journal-title":"Nature reviews Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/2010.7.FOCUS10153","article-title":"Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas","volume":"29","author":"PG Campbell","year":"2010","journal-title":"Neurosurgical focus"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists","volume":"19","author":"CM dos Santos Silva","year":"2011","journal-title":"Obesity"},{"key":"ref26","first-page":"366","article-title":"The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy","volume":"64","author":"O Serri","year":"2006","journal-title":"Clinical endocrinology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1530\/EJE-11-1119","article-title":"The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases","volume":"166","author":"M Wang","year":"2012","journal-title":"European journal of endocrinology\/European Federation of Endocrine Societies"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.bbrc.2005.04.026","article-title":"Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue","volume":"331","author":"L Nilsson","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","article-title":"Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry","volume":"164","author":"S Fieffe","year":"2011","journal-title":"European journal of endocrinology\/European Federation of Endocrine Societies"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/jc.2008-1546","article-title":"Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study","volume":"94","author":"A Colao","year":"2009","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e1002400","DOI":"10.1371\/journal.pgen.1002400","article-title":"The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis","volume":"7","author":"T Tateno","year":"2011","journal-title":"PLoS Genet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/0008-5472.CAN-11-3654","article-title":"Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis","volume":"72","author":"C Heinzle","year":"2012","journal-title":"Cancer research"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"A Giustina","year":"2010","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cmet.2013.05.002","article-title":"The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes","volume":"17","author":"S Ezzat","year":"2013","journal-title":"Cell Metab"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0073543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T16:08:35Z","timestamp":1563898115000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0073543"}},"subtitle":[],"editor":[{"given":"Raul M.","family":"Luque","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,9,9]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0073543","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,9]]}}}